AGC Biologics and Evax Partner to Advance Promising Equine Allergy Vaccine Candidate
The CDMO supports clinical stages using its Heidelberg site’s microbial-based biologics services Seattle, Sept. 07, 2022 (GLOBE NEWSWIRE) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with Evax, a developer of equine vaccines to treat chronic diseases, respiratory disorders and allergies. Through this partnership, Evax […]